论文部分内容阅读
目的 :探讨急性白血病 MDR1 + / CD34+表型的临床意义。方法 :采用流式细胞仪及对碘硝基四唑盐(INT)细胞毒检测法 ,分析了 5 1例初治及 17例复发急性白血病患者细胞的表面分化抗原及 MDR1 + 基因编码的p170阳性率 ,并用 INT法的体外药敏试验进行对照。结果 :MDR1 + 与 CD34+ 有显著相关性 (r =0 .842 ,P <0 .0 1) ,而与 CD1 3、CD1 4 、CD1 5 、CD33、HL A- DR等其它髓系抗原无关 ;MDR1 + / CD34+表型细胞较 MDR1 - / CD34-表型细胞缓解率、生存期、缓解期显著缩短。结论 :急性白血病 MDR1 + / CD34+ 表型可作为白血病预后不良的指标。
Objective: To investigate the clinical significance of MDR1 + / CD34 + phenotype in acute leukemia. Methods: Flow cytometry and iodinated nitrotetrazolium (INT) cytotoxicity assay were used to analyze the differentially expressed antigens and the p170 positive cells of MDR1 + gene in 51 untreated and 17 relapsed acute leukemia patients Rate, and the use of INT method in vitro susceptibility testing control. Results: There was a significant correlation between MDR1 + and CD34 + (r = 0.8242, P <0.01), but not with other myeloid antigens such as CD13, CD14, CD15, + / CD34 + phenotype cells than MDR1 - / CD34- phenotype cells remission rate, survival, remission was significantly shorter. Conclusion: MDR1 + / CD34 + phenotype of acute leukemia can be used as an indicator of poor prognosis of leukemia.